Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: Edison Investment Research
$10.00
Provider: GlobalData
$125.00
Provider: Edison Investment Research
$10.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

e-Therapeutics PLC announces recruitment resumes into US phase I ETS2101 brain cancer trial


Thursday, 8 May 2014 02:00am EDT 

e-Therapeutics PLC:Says US Food and Drug Administration (FDA) approves resumption of recruitment of new patients into Company's investigator-led Phase Ia study of ETS2101 in brain cancer.Says it is conducted at University of California San Diego Moores Cancer Centre.Recruitment was temporarily paused due to drug storage issue which has been resolved to satisfaction of FDA, allowing the trial to continue to higher doses in further cohorts of patients.Patients who had received treatment with ETS2101 at time of temporary halt in recruitment were able to continue to be dosed in accordance with trial protocols. 

Related Company News

Company Quote

29.0
0.0 +0.00%
18 Sep 2014